相似文献
1
Fitness of neuraminidase inhibitor-resistant influenza A viruses.
Curr Opin Virol. 2011 Dec;1(6):574-81. doi: 10.1016/j.coviro.2011.08.006. Epub 2011 Oct 1.
2
Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.
PLoS One. 2018 Jan 11;13(1):e0190877. doi: 10.1371/journal.pone.0190877. eCollection 2018.
3
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1(Suppl 1):25-36. doi: 10.1111/irv.12047.
4
Incidence of antiviral drug resistance markers among human influenza A viruses in the Eastern Mediterranean Region, 2005-2016.
Infect Genet Evol. 2019 Jan;67:60-66. doi: 10.1016/j.meegid.2018.10.023. Epub 2018 Oct 30.
5
[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Pathol Biol (Paris). 2010 Apr;58(2):e69-78. doi: 10.1016/j.patbio.2010.01.011. Epub 2010 Mar 19.
6
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Antivir Ther. 2012;17(1 Pt B):159-73. doi: 10.3851/IMP2067. Epub 2012 Feb 3.
7
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
J Virol. 2010 Oct;84(19):9800-9. doi: 10.1128/JVI.00296-10. Epub 2010 Jul 21.
8
Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
J Virol. 2016 Apr 14;90(9):4637-4646. doi: 10.1128/JVI.00013-16. Print 2016 May.
9
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
Antiviral Res. 2002 Aug;55(2):307-17. doi: 10.1016/s0166-3542(02)00053-0.
10
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Antiviral Res. 2017 Oct;146:12-20. doi: 10.1016/j.antiviral.2017.08.004. Epub 2017 Aug 10.
引用本文的文献
1
Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors.
J Antimicrob Chemother. 2023 Jul 5;78(7):1649-1657. doi: 10.1093/jac/dkad145.
2
Phenotypic effects of mutations observed in the neuraminidase of human origin H5N1 influenza A viruses.
PLoS Pathog. 2023 Feb 6;19(2):e1011135. doi: 10.1371/journal.ppat.1011135. eCollection 2023 Feb.
3
Evolution and Antigenic Advancement of N2 Neuraminidase of Swine Influenza A Viruses Circulating in the United States following Two Separate Introductions from Human Seasonal Viruses.
J Virol. 2021 Sep 27;95(20):e0063221. doi: 10.1128/JVI.00632-21. Epub 2021 Aug 11.
4
Targeting TLR4 Signaling to Blunt Viral-Mediated Acute Lung Injury.
Front Immunol. 2021 Jul 2;12:705080. doi: 10.3389/fimmu.2021.705080. eCollection 2021.
5
Influenza "Trains" the Host for Enhanced Susceptibility to Secondary Bacterial Infection.
mBio. 2019 May 7;10(3):e00810-19. doi: 10.1128/mBio.00810-19.
6
A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets.
Cell Host Microbe. 2017 Nov 8;22(5):615-626.e8. doi: 10.1016/j.chom.2017.09.008. Epub 2017 Oct 19.
7
Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms.
PLoS One. 2017 Jul 10;12(7):e0180582. doi: 10.1371/journal.pone.0180582. eCollection 2017.
8
Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in Ferrets.
PLoS One. 2016 Jul 28;11(7):e0159847. doi: 10.1371/journal.pone.0159847. eCollection 2016.
9
High-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase Activity.
PLoS One. 2016 May 27;11(5):e0156400. doi: 10.1371/journal.pone.0156400. eCollection 2016.
10
The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern.
J Gen Virol. 2016 Jun;97(6):1311-1323. doi: 10.1099/jgv.0.000444. Epub 2016 Mar 2.
本文引用的文献
1
Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010.
Antiviral Res. 2011 Oct;92(1):81-9. doi: 10.1016/j.antiviral.2011.07.004. Epub 2011 Jul 13.
2
Competitive transmissibility and fitness of oseltamivirsensitive and resistant pandemic influenza H1N1 viruses in ferrets.
Influenza Other Respir Viruses. 2011 May;5(Suppl 1):79-82.
3
Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.
Antimicrob Agents Chemother. 2011 Oct;55(10):4718-27. doi: 10.1128/AAC.00316-11. Epub 2011 Jul 5.
4
5
Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
J Virol. 2011 May;85(10):4667-72. doi: 10.1128/JVI.00047-11. Epub 2011 Mar 2.
6
Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009.
J Infect Dis. 2011 Mar 15;203(6):838-46. doi: 10.1093/infdis/jiq124.
7
Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States.
Emerg Infect Dis. 2011 Feb;17(2):255-7. doi: 10.3201/eid1702.101724.
8
The contribution of animal models to the understanding of the host range and virulence of influenza A viruses.
Microbes Infect. 2011 May;13(5):502-15. doi: 10.1016/j.micinf.2011.01.014. Epub 2011 Jan 27.
9
Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets.
J Infect Dis. 2011 Feb 1;203(3):348-57. doi: 10.1093/infdis/jiq067. Epub 2010 Dec 20.
10
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.
Zotero 插件